



Emisphere to Present at 12th Annual BIO CEO & Investor Conference

CEDAR KNOLLS, N.J., Feb 02, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen^(R) Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present at the 12th Annual BIO CEO & Investor Conference at 2:30 PM EST on Tuesday, February 9, 2010. The BIO CEO Conference is being held at the Waldorf-Astoria Hotel in New York City.

Emisphere's presentation at BIO CEO will be webcast live, the day of the conference, and will be available at <http://www.veracast.com/webcasts/bio/ceoinvestor2010/61211345.cfm>. A replay of the Company's webcast can be accessed via this link approximately one hour after the conclusion of the live event and until May 11, 2010. A link to Emisphere's presentation will also be posted on the Investor Relations section of the Company's website a www.emisphere.com.

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen^(R) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen^(R) Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The website is: www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates, savings and efficiencies attainable by Emisphere in the future, and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere to realize savings from efficiencies in staffing and facilities, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 13, 2008 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed on November 6, 2008.

SOURCE: Emisphere Technologies, Inc.

For Media Relations:

West Mill Communications
Jeffrey A. Winton, 908-872-2682
jeffwmm@aol.com

or

Emisphere Technologies
Daria Palestina, 973-532-8002
dpalestina@emisphere.com

or

For Investor Relations:

Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

